Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.62B | 16.54B | 16.77B | 16.29B | 16.00B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.62B | 16.54B | 16.77B | 16.29B | 16.00B |
| Cost of Revenue | 8.45B | 8.48B | 8.41B | 8.23B | 8.17B |
| Gross Profit | 8.17B | 8.06B | 8.36B | 8.06B | 7.83B |
| SG&A Expenses | 3.73B | 3.70B | 3.65B | 3.57B | 3.54B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 10.00M | -9.00M | -1.00M | 11.00M | -12.00M |
| Total Operating Expenses | 13.19B | 13.17B | 13.04B | 12.80B | 12.66B |
| Operating Income | 3.42B | 3.37B | 3.73B | 3.49B | 3.34B |
| Income Before Tax | -519.00M | -1.28B | -529.00M | -143.00M | -821.00M |
| Income Tax Expenses | 801.00M | 675.00M | 688.00M | 607.00M | -39.00M |
| Earnings from Continuing Operations | -1.32K | -1.96K | -1.22K | -750.00 | -782.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 34.00M | 320.00M | 258.00M | 297.00M | 303.00M |
| Net Income | -1.29B | -1.64B | -959.00M | -453.00M | -479.00M |
| EBIT | 3.42B | 3.37B | 3.73B | 3.49B | 3.34B |
| EBITDA | 4.45B | 4.43B | 4.79B | 4.57B | 4.46B |
| EPS Basic | -1.14 | -1.45 | -0.84 | -0.40 | -0.43 |
| Normalized Basic EPS | 1.39 | 1.61 | 1.74 | 1.64 | 1.55 |
| EPS Diluted | -1.15 | -1.46 | -0.86 | -0.41 | -0.44 |
| Normalized Diluted EPS | 1.38 | 1.61 | 1.73 | 1.63 | 1.54 |
| Average Basic Shares Outstanding | 4.54B | 4.52B | 4.51B | 4.50B | 4.49B |
| Average Diluted Shares Outstanding | 4.56B | 4.52B | 4.53B | 4.53B | 4.52B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |